Drug Profile
ABBV 084
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator AbbVie
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in USA
- 15 Jan 2016 Phase-I clinical trials in Systemic lupus erythematosus in USA (unspecified route)